A research programme by the Access to Medicine Foundation
The foundation

Access to Medicine Foundation

The Foundation stimulates and guides pharmaceutical companies to do more to improve access to medicine. It is an independent non-profit organisation.
Our programmes

Access to Medicine Index

Ranks 20 of the world’s largest pharmaceutical companies based on their efforts to address access to medicine, including in strategy, governance, R&D and pricing. By publicly recognising the best performers, the Index spurs companies to compete to be the best.

Antimicrobial Resistance Benchmark

Tracks what the 17 most active companies in antimicrobial R&D and manufacturing are doing to bring antimicrobial resistance under control. By assessing the level of action, it provides a reality check on progress against AMR.

Access to Vaccines Index

Reports what vaccine companies are doing to ensure all children can be immunised wherever they live. By uncovering what is working and where, this Index helps ensure vaccine markets also reach the poorest and most remote communities.
Type search term(s) and press enter
Often searched for
Index Ranking Vacancies 10-year analysis R&D pipelines AMR antibiotics Investors

Results

Explore the latest analyses of pharma company action

The 2021 Access to Medicine Index uses 33 metrics to examine how 20 pharmaceutical companies respond to the need for better access to medicine in 106 low- and middle-income countries and for 82 diseases, conditions and pathogens. Here are the results.  

19 Results

Filter Results

19 FindingsResults Clear selected filters
All companies selected
All topics selected
All regions selected
All diseases selected
See results
Key finding: COVID-19

R&D for COVID-19 has increased, yet other pandemic risks go unaddressed

Despite years of warnings that novel coronaviruses were among the pathogens most likely to cause a global health emergency, the pharmaceutical industry, as well as society at large, was ill-prepared for the COVID-19 pandemic.
Key finding: Access planning

Eight companies adopt processes to systematically address access to medicine for all new products
Key finding: Access strategies

Less than half of key products are covered by pharma companies’ access strategies in poorer countries
Index long read

How are companies responding to COVID-19 and are they prepared for the next potential pandemic?

The COVID-19 pandemic has demonstrated companies’ ability to rapidly mobilise in the face of priorities, but how can we better prepare for the next pandemic? This special report describes how some companies responded to COVID-19 and wh...
Behind the ranking numbers

Pharma companies inch forward in integrating access to medicine into business practices
Progress analysis

Is the industry doing more to improve access to medicine?
Project development

Are pharma companies developing health products that are urgently needed and offer a clear public health benefit?
Access planning

Do pharma companies plan ahead to ensure their products are accessible to patients in low- and middle-income countries?
Governance, strategy and business

How do companies prioritise access to medicine?
Access strategies: Context Part I

How do pharma companies ensure worldwide access to their products?

This part one of a four part series, describes how the Index assessed whether companies tailor their access strategies to reach patients across the income pyramid and how they overcome-specific access barriers.
Access strategies: Results Part II

Do companies extend access terms for countries outside supranational agreements?
Access strategies: Results Part III

What does access look like for healthcare practitioner-administered products?
Access strategies: Results Part IV

What does access look like for self-administered products?
Product Donations

Are companies’ donations programmes sustaining elimination efforts?
Licensing and IP management

Are companies engaging in voluntary licensing to expand access?
Registration

Which markets do pharmaceutical companies target for registration?
Inclusive Business Models

Are companies reaching into low-income markets?
Health system strengthening

How do companies overcome gaps in local health systems?
Supply

How do companies help safeguard the supply and quality of their products?

Get in touch

Back to top |